Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1. chromosomal instability. While this induces cell cycle arrest, cancer cells lacking G2/M checkpoint controls might continue to proliferate despite the BARD1-induced chromosomal instability. These features of BARD1 may make it AIM-100 a genome permutator and a driver of continuous uncontrolled proliferation of cancer cells. mRNA isoforms of variable exon composition are expressed in human and murine cancers. Of 20 mRNAs identified in cancer tissues, at least 11 are protein coding (Supplementary Figure S1) [3, 13C19]. The full length (FL) BARD1 mRNA includes 11 exons and encodes a protein comprising an N-terminal RING-finger domain, three ankyrin repeats (ANK) and two C-terminal BRCT domains. While the RING domain is important for the BRCA1-BARD1 heterodimer formation and E3 ubiquitin ligase activity [6, 20, 21], the BRCT domains are involved in phospho-epitope binding [22, 23] and ADP-ribosylation [24]. The BARD1 C-terminus, including ANK and BRCT, has been shown to interact with a number of proteins important for carcinogenesis, such as p53 [13, 25, 26], CstF-50 [27C29], Ewing’s Sarcoma oncoprotein [30], NF-kB [31], Aurora kinases [8, 32], and estrogen receptor- [33]. It appears AIM-100 plausible that BARD1 isoforms of different domain composition may be involved in the same pathways as FL BARD1, yet play different roles or compete for normal BRCA1-BARD1 functions. Further evidence for a functional link between malignant transformation CDC25A and alternatively spliced BARD1 isoforms came with the identification of as a neuroblastoma predisposition gene in a genome wide association study. Single nucleotide polymorphisms (SNPs) in introns of correlated with a subclass of highly aggressive and treatment AIM-100 resistant neuroblastoma [34C36] and with elevated expression of the alternatively spliced BARD1 isoform [32]. repression of BARD1 caused SNP genotype-specific inhibition of cell proliferation in neuroblastoma cells, and overexpression of BARD1, but not FL BARD1, led to the transformation of non-malignant fibroblasts, suggesting that BARD1 is an oncogenic driver of high-risk neuroblastoma [32]. The cellular functions of BARD1 isoforms that are associated with cancer are still unclear. There is accumulating evidence that BARD1 isoforms may antagonize the function of the BARD1-BRCA1 E3 ubiquitin ligase. In particular, BARD1, lacking the BRCA1-interacting RING domain, binds and stabilizes the Aurora A and B kinases during mitosis, while the overexpression of either BARD1 or BRCA1 leads to degradation of the Aurora A and B kinases [8, 32], suggesting that BARD1 antagonizes this function. BARD1, an isoform that lacks RING and ANK, regions critical for interaction with BRCA1 and p53, respectively [13, 25, 37C39], was found in all types of cancer investigated so far, of human and murine origin [14C19, 32], and was specifically correlated with highly aggressive clear cell ovarian cancer [14]. Interestingly, BARD1 is as AIM-100 well expressed in normal human cytotrophoblasts [32, 40] and has functions as regulator of estrogen signaling [33]. Here we investigated the phenotype of BARD1 overexpression and was defined using Student’s (Figure ?(Figure2A).2A). While mock injected embryos divided and developed normally, as well as the embryos injected with an expression construct for the pro-proliferative isoform BARD1 [8, 32], many of the oocytes injected with the YFP-BARD1 expression vector were arrested at the 2 2 or 4-cell stage, and all arrested embryos were YFP-positive (Figure ?(Figure2A2A). Open in a separate window Figure 2 BARD1 blocks cell proliferation in vivo(A) Cell divisions of fertilized oocytes after injection with BARD1 or YFP-BARD1 (BARD1) transgenes. Mouse oocytes injected at the one-cell stage with control injection (WT), the YFP- BARD1 transgene, or BARD1 (grey scale and fluorescent green), were monitored during the mouse embryonic development to the 4 and 8 cell and blastula stage after 2.5 and 3.5 days, respectively. YFP-BARD1 injected mouse eggs showed developmental arrest at 2 or 4-cell stage after embryonic day 3.5. Experiments were performed on several consecutive days with similar results. (B) Immunofluorescent staining of 8-cell and morula stage wild type mouse embryos with anti-BARD1 antibody directed against exon 4 for expression of endogenous BARD1. (C) Weight loss of the YFP-BARD1 expressing transgenic mice. Weight gain or loss was monitored of YFP-BARD1 Cre (TG/-; Cre/-) or BL6 Cre mice (Cre/-) upon tamoxifen driven induction. Red arrow indicates death* of one YFP-BARD1 Cre (TG / -;Cre /-) animal. The error bars show the standard deviation.. *Sacrificed because of too rapid weight loss. These results confirmed a growth inhibitory function of BARD1 in non-malignant cells and (Figures ?(Figures1D,1D, ?,2A;2A; Supplementary Figure S2). Moreover, we found.